CompletedPhase 2NCT01081431
Safety of Lenalidomide and Markers for Disease Progression in Patients With International Prognostic Scoring System (IPSS) Low- or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) With Isolated del5q
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- Principal Investigator
- Ulrich Germing, Prof.Heinrich-Heine University, Duesseldorf
- Intervention
- Lenalidomide(drug)
- Enrollment
- 91 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2018
Study locations (12)
- Charité - Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
- Universitätsklinikum Carl Gustav Carus an der TU Dresden, Dresden, Germany
- Kath. Klinikum Duisburg, Duisburg, Germany
- Heinrich Heine Universität Düsseldorf, Düsseldorf, Germany
- Klinikum der J.W. Goethe Universität, Frankfurt, Germany
- Universitätsklinikum Freiburg, Freiburg im Breisgau, Germany
- Universitätsklinikum Göttingen, Göttingen, Germany
- Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany
- Medizinische Hochschule Hannover, Hanover, Germany
- Universitätsklinikum Mannheim, Mannheim, Germany
- TU München - Klinikum rechts der Isar, München, Germany
- Universitätsklinikum Ulm, Ulm, Germany
Collaborators
ClinAssess GmbH
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01081431 on ClinicalTrials.govOther trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Additional recruiting or active studies for the same condition.